W.J. Qin

发表

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

A. Zhou, T. Sun, X.Q. Yan, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Oncotargets and Therapy Dovepress Dovepress Heme Oxygenase-1 Is a Predictive Biomarker for Therapeutic Targeting of Advanced Clear Cell Renal Cell Carcinoma Treated with Sorafenib or Sunitinib

C. Tian, Fu-li Wang, W.J. Qin, 2022 .